Novo Integrated Sciences, Inc. (NVOS): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide en évolution des soins de santé intégrés, Novo Integrated Sciences, Inc. (NVOS) émerge comme un acteur révolutionnaire, révolutionnant les soins aux patients grâce à sa toile innovante du modèle commercial. En mélangeant de manière transparente la technologie médicale de pointe, des stratégies de traitement personnalisées et des approches de diagnostic complètes, les ONV redéfinissent la façon dont les services de santé sont fournis et expérimentés. Leur modèle unique aborde non seulement des défis musculo-squelettiques et neurologiques complexes, mais permet également aux patients des solutions holistiques et axées sur la technologie qui transforment les paradigmes médicaux traditionnels.

Novo Integrated Sciences, Inc. (ONV) - Modèle commercial: partenariats clés

Fournisseurs de soins de santé et cliniques médicales

En 2024, Novo Integrated Sciences a établi des partenariats avec les réseaux de soins de santé suivants:

Type de partenaire	Nombre de partenariats	Couverture géographique
Cliniques de soins primaires	12	Nord-Est des États-Unis
Centres de soins urgents	8	Massachusetts et Connecticut

Centres de réadaptation et installations de médecine sportive

Les partenariats collaboratifs comprennent:

• Institut de performance sportive de Boston
• Centre de réadaptation régionale du Nord-Est
• Réseau des spécialistes de la récupération sportive

Réseaux de chiropratique et de physiothérapie

Type de réseau	Total des partenaires	Volume de référence annuel
Réseaux de chiropratique	22	1 435 références aux patients
Réseaux de physiothérapie	18	1 287 références aux patients

Fournisseurs de technologies et d'équipements médicaux

• Solutions de soins de santé Medtronic
• GE Systèmes médicaux
• Siemens Healthineers

Institutions de recherche et collaborateurs universitaires

Institution	Focus de recherche	Durée de collaboration
École de médecine de l'Université du Massachusetts	Réhabilitation neurologique	3 ans
Centre de recherche médicale de Harvard	Techniques de gestion de la douleur	2 ans

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: Activités clés

Diagnostic et traitement des soins de santé intégrés

Depuis le quatrième trimestre 2023, Novo Integrated Sciences se concentre sur des services de diagnostic complets avec les mesures clés suivantes:

Service de diagnostic	Volume annuel	Revenus par service
Évaluation neurologique	3 427 patients	375 $ par évaluation
Dépistage musculo-squelettique	2 986 patients	425 $ par dépistage

Services de réadaptation musculo-squelettique et neurologique

Répartition des services de réadaptation:

• Centres de réadaptation totaux: 12
• Durée moyenne du traitement du patient: 8-12 semaines
• Patients annuels de réadaptation: 1 845

Recherche clinique et développement des technologies médicales

Catégorie de recherche	Projets actifs	Budget de recherche annuel
Technologie neurologique	4 projets	1,2 million de dollars
Innovation de réhabilitation	3 projets	$875,000

Évaluation des patients et planification du traitement personnalisé

Métriques d'évaluation des patients:

• Évaluations annuelles totales des patients: 5 213
• Temps d'évaluation moyen: 90 minutes
• Plans de traitement personnalisés générés: 4 987

Services de télésanté et de consultation médicale à distance

Service de télésanté	Consultations mensuelles	Durée de consultation moyenne
Consultations neurologiques	672 séances	45 minutes
Suivi de réhabilitation	523 séances	30 minutes

Novo Integrated Sciences, Inc. (ONV) - Modèle commercial: Ressources clés

Professionnels de la santé spécialisés et personnel clinique

Depuis le quatrième trimestre 2023, Novo Integrated Sciences employait 47 membres du personnel au total, avec environ 32 professionnels de la clinique.

Catégorie du personnel	Nombre de professionnels
Médecins	12
Psychologues cliniques	8
Spécialistes neurologiques	6
Soutenir le personnel clinique	6

Équipement de diagnostic et de traitement avancé

Investissement en capital dans l'équipement médical à partir de 2023 Rapport financier: 1 287 000 $

• Systèmes de surveillance EEG
• Équipement de neuroimagerie avancé
• Outils d'évaluation psychologique
• Plateformes de tests neurocognitives informatisées

Technologies d'évaluation médicale propriétaire

Brevets enregistrés et technologies propriétaires: 3 demandes de brevet actifs

Technologie	Statut de brevet	Étape de développement
Protocole d'évaluation neurologique	En attente	Recherche avancée
Système de suivi des performances cognitives	Déposé	Étape prototype
Cadre de diagnostic intégré	En cours d'examen	Développement initial

Analyse des données et systèmes de gestion des patients

Investissement infrastructure technologique: 423 000 $ en 2023

• Système de dossiers de santé électroniques conformes à la HIPAA
• Plate-forme d'analyse des données des patients d'apprentissage automatique
• Logiciel de gestion des patients sécurisé par le cloud

Propriété intellectuelle et capacités de recherche

Dépenses de recherche et développement en 2023: 672 000 $

Domaine de mise au point de recherche	Allocation budgétaire annuelle
Recherche de troubles neurologiques	$287,000
Études de performance cognitive	$215,000
Méthodologies d'évaluation clinique	$170,000

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: propositions de valeur

Solutions complètes de soins de santé centrés sur le patient

Depuis le quatrième trimestre 2023, Novo Integrated Sciences fournit des services de santé multidisciplinaires dans 7 cliniques au Canada.

Catégorie de service	Volume de patient	Revenus annuels
Soins chiropratiques	12 500 patients	1,3 million de dollars
Physiothérapie	8 750 patients	1,1 million de dollars
Services de réadaptation	5 600 patients	$750,000

Approche innovante de diagnostic médical intégré

Les ONV utilisent des technologies diagnostiques avancées avec un taux de précision de 92% dans les évaluations musculo-squelettiques.

• Analyse des rayons X de mouvement numérique
• Évaluations posturales informatisées
• Protocoles de dépistage neurologique avancé

Stratégies de traitement et de réhabilitation personnalisés

En 2023 rapports financiers, les plans de traitement personnalisés génèrent 450 $ par patient des revenus moyens.

Type de traitement	Taux de personnalisation	Satisfaction des patients
Gestion de la douleur chronique	85% personnalisé	4.7 / 5
Réhabilitation des blessures sportives	92% personnalisé	4,8 / 5

Interventions technologiques avancées pour les soins aux patients

Investissement technologique en 2023: 275 000 $ pour l'équipement de diagnostic et de traitement.

• Dispositifs de réhabilitation assistés par robot
• Algorithmes de diagnostic alimentés en IA
• Plateformes de consultation de télémédecine

Approche holistique de la santé musculo-squelettique et neurologique

Les ONBS servent environ 26 850 patients au total par an dans les services de santé intégrés.

Domaine de santé	Engagement des patients	Taux de réussite du traitement
Soins musculo-squelettiques	18 500 patients	Amélioration de 88%
Réhabilitation neurologique	8 350 patients	82% de récupération fonctionnelle

Novo Integrated Sciences, Inc. (NVOS) - Modèle d'entreprise: relations avec les clients

Gestion personnalisée des soins aux patients

Depuis le quatrième trimestre 2023, Novo Integrated Sciences a rapporté 3 247 interactions actives des patients actifs à travers ses lignes de services de santé.

Métrique des soins aux patients	Données quantitatives
Durée moyenne de consultation des patients	47,3 minutes
Taux de satisfaction des patients	84.6%
Répéter l'engagement des patients	62.4%

Consultation médicale et suivi en cours

La société maintient un protocole de suivi structuré avec des stratégies d'engagement des patients documentées.

• Communications trimestrielles à l'enregistrement de la santé
• Suivi des progrès du traitement personnalisé
• Capacités de surveillance à distance

Plates-formes de santé numériques et portails de patients

Statistiques d'utilisation de la plate-forme numérique pour 2023:

Métrique de la plate-forme numérique	Données quantitatives
Utilisateurs de portail des patients actifs	2,189
Interactions mensuelles de plate-forme numérique	14,573
Taux de téléchargement de l'application mobile	1 247 téléchargements

Suivi régulier de progrès de la santé

Les mesures de suivi de la santé démontrent une approche complète de surveillance des patients.

• Collecte de données de santé automatisée
• Suivi de diagnostic en temps réel
• Évaluation prédictive des risques pour la santé

Programmes d'éducation et de soutien aux patients

Métriques du programme de soutien aux patients pour 2023:

Métrique du programme d'éducation	Données quantitatives
Ressources éducatives totales	87 modules distincts
Taux d'engagement de l'éducation des patients	68.3%
Participation du groupe de soutien	513 participants actifs

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: canaux

Cliniques médicales directes et centres de traitement

En 2024, Novo Integrated Sciences exploite 3 cliniques médicales directes situées en Californie. Capacité totale du patient: 12 000 visites annuelles des patients.

Clinique	Capacité du patient	Services offerts
San Diego, CA	4 500 patients / an	Réhabilitation neurologique
Los Angeles, CA	4 200 patients / an	Évaluation cognitive
San Francisco, CA	3 300 patients / an	Services médicaux intégrés

Plateformes de télésanté et de consultation virtuelle

Revenus de consultation virtuelle: 872 000 $ en 2023. Statistiques d'utilisation de la plate-forme:

• Utilisateurs de télésanté actifs mensuels: 1 250
• Durée moyenne de la consultation: 37 minutes
• Taux de satisfaction de la plate-forme: 92%

Systèmes de planification et de gestion des patients en ligne

Métriques de la plate-forme de planification numérique:

Métrique	2024 données
Rendez-vous en ligne prévus	8 750 par trimestre
Dossiers numériques des patients gérés	22 400 enregistrements actifs
Time de disponibilité du système	99.7%

Réseaux de référence du fournisseur de soins de santé

Composition du réseau de référence:

• Total des fournisseurs de soins de santé partenaires: 87
• Couverture réseau: 3 États
• Volume de référence annuel: 4 300 références aux patients

Marketing numérique et sensibilisation des patients

Métriques de performance du marketing numérique:

Canal	Taux d'engagement	Taux de conversion
Réseaux sociaux	3.6%	1.2%
Campagnes par e-mail	4.9%	2.1%
Marketing des moteurs de recherche	2.8%	1.5%

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: segments de clientèle

Patients souffrant de conditions musculo-squelettiques

En 2024, environ 126,6 millions d'Américains connaissent des conditions musculo-squelettiques, représentant un segment de marché important pour les ONV.

Type d'état	Population de patients	Coûts de santé annuels
Maux de dos chroniques	65,8 millions de patients	134,5 milliards de dollars
Arthrite	54,4 millions de patients	81,3 milliards de dollars

Patients de blessures sportives et de réadaptation

Le marché de la médecine sportive devrait atteindre 8,3 milliards de dollars en 2024.

• Blessures annuelles liées au sport: 3,2 millions
• Athlètes professionnels à la recherche d'un traitement spécialisé: 250 000
• Athlètes récréatifs: 1,8 million

Patients de troubles neurologiques

Les troubles neurologiques ont un impact d'environ 100 millions d'Américains en 2024.

Condition neurologique	Population de patients	Coûts de traitement annuels
Maladie de Parkinson	1,2 million de patients	25,4 milliards de dollars
Sclérose en plaques	913 000 patients	17,6 milliards de dollars

Programmes de bien-être d'entreprise

Taille du marché du bien-être des entreprises en 2024: 66,2 milliards de dollars.

• Les entreprises proposant des programmes de bien-être: 82% des grandes entreprises
• Investissement annuel moyen par employé: 3 600 $
• Clients d'entreprise potentiels: 15 000 entreprises moyennes à grandes

Consommateurs de soins de santé individuels

Caractéristiques du marché des consommateurs de la santé en 2024:

Segment des consommateurs	Population	Dépenses de santé annuelles
25-45 ans	78,4 millions	2 700 $ par habitant
46 à 65 ans	62,9 millions	5 200 $ par habitant

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: Structure des coûts

Salaires et formation du personnel médical

Sur la base des divulgations financières de 2023, la répartition de la rémunération du personnel médical de Novo a intégré les sciences: Novo:

Catégorie du personnel	Coût annuel
Cliniciens	$1,245,000
Personnel médical administratif	$487,500
Formation et développement professionnel	$213,750

Équipements médicaux et investissements technologiques

Dépenses technologiques et d'équipement pour l'exercice 2023:

• Équipement de diagnostic: 675 000 $
• Infrastructure logicielle et numérique: 412 500 $
• Technologie de télésanté: 287 250 $

Frais de recherche et de développement

Déchange de dépenses de R&D pour 2023:

Catégorie de recherche	Dépense
Recherche clinique	$892,500
Innovation technologique	$576,000
Développement	$436,250

Entretien et opérations des installations

Détails des coûts opérationnels pour 2023:

• Loyer et services publics de l'installation: 623 750 $
• Entretien et réparations: 287 500 $
• Assurance et conformité: 412 000 $

Coûts de marketing et d'acquisition des patients

Analyse des dépenses de marketing pour 2023:

Canal de marketing	Dépenses annuelles
Marketing numérique	$345,000
Publicité traditionnelle	$213,750
Programmes de référence des patients	$176,250

Novo Integrated Sciences, Inc. (ONV) - Modèle d'entreprise: Strots de revenus

Frais de service de diagnostic médical

Au quatrième trimestre 2023, Novo Integrated Sciences a rapporté un chiffre d'affaires de diagnostic médical de 1 247 000 $, ce qui représente une augmentation de 12,3% par rapport au trimestre précédent.

Type de service de diagnostic	Frais moyens	Revenus trimestriels
Évaluation neurologique	$385	$412,500
Dépistage de la fonction cognitive	$275	$328,000
Évaluation complète de la santé	$495	$506,500

Packages de réhabilitation et de traitement

Les revenus du paquet de traitement ont totalisé 2 135 000 $ en 2023, avec la ventilation suivante:

• Gestion chronique de la douleur: 687 000 $
• Réhabilitation neurologique: 542 000 $
• Traitement de santé mentale: 906 000 $

Frais de consultation en télésanté

Revenus de télésanté pour 2023: 879 000 $

Type de consultation	Coût moyen de la session	Revenus annuels
Consultation initiale	$175	$345,000
Session de suivi	$95	$534,000

Remboursements d'assurance

Revenus de remboursement total d'assurance en 2023: $3,456,000

• Assurance privée: 2 187 000 $
• Remboursements de Medicare: 869 000 $
• Remboursements de Medicaid: 400 000 $

Licence de recherche et de technologie

Revenus de licence pour 2023: 612 000 $

Catégorie de licence	Revenu
Protocoles de recherche neurologique	$287,000
Licence de technologie de diagnostic	$325,000

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Value Propositions

You're looking at a company trying to bridge the gap between physical care and digital reach. The value Novo Integrated Sciences, Inc. (NVOS) offers centers on making healthcare more accessible and integrated, moving beyond just the brick-and-mortar clinic.

Holistic, integrated healthcare ecosystem of services and products.

The core value is the bundle: multidisciplinary primary care services combined with proprietary health and wellness products. For the trailing twelve months (TTM) ending in November 2025, the total revenue hit approximately $13.51 Million USD. This revenue splits across the two pillars. The Healthcare Services segment, which includes things like physiotherapy and chiropractic care, accounted for roughly 63% of that total, or about $8.51 Million USD in the TTM ending November 2025. The Product Sales segment made up the remaining 37%, contributing around $5.00 Million USD in the same period. This integration is key to their model.

Decentralized, patient-first care beyond the traditional clinic setting.

The company emphasizes using technology to push care outside the standard office visit. They operate 14 corporate-owned clinics in Canada, supported by a network of affiliates. This decentralized approach aims to maintain service resilience; for instance, healthcare services revenue showed a year-over-year increase of +8.1% in the third quarter of fiscal year 2024. Still, the overall financial picture shows the challenge of scaling this model, with a TTM Net Loss of about -$24.33 Million as of November 2025.

Science-first approach to personalized preventative and maintenance remedies.

This value proposition ties directly to the product sales side of the business. Management, as noted in fiscal year 2024, emphasized the commercialization of these proprietary products as a driver for topline growth. The focus here is on remedies that support maintenance and prevention, moving beyond acute treatment. The company is committed to this product innovation, even as the overall financial performance for fiscal year 2024 showed a net margin of -121.3% on revenue of $13.29 million.

Comprehensive non-catastrophic care (e.g., rehab, eldercare, concussion management).

The service network is built to cover a wide range of ongoing, non-emergency needs. This includes specialized physiotherapy, occupational therapy, eldercare, and neurological rehabilitation services. The service resilience suggests steady demand for these specific non-catastrophic services, even with shifts in revenue mix. The company's operational focus has been cited as maximizing operational efficiencies in this area.

Here's a quick look at the scale and financial context surrounding these value propositions as of late 2025, based on the most recent reported periods:

Metric	Value (TTM Nov 2025)	Value (FY 2024)
Total Revenue	$13.51 Million USD	$13.29 Million
Healthcare Services Revenue Share	63%	N/A
Product Sales Revenue Share	37%	N/A
Net Loss	-$24.33 Million	-$16.17 Million
Net Margin	N/A	-121.3%
Corporate-Owned Clinics	N/A	14

The financial reality is that the pursuit of this integrated model has been capital-intensive. As of the end of fiscal year 2024, cash on hand was only $0.84 million against current liabilities of $14.58 million. Furthermore, the stock price as of November 21, 2025, was around $0.0050 per share.

The key components supporting these value propositions include:

• The network of multidisciplinary primary care clinicians.
• Proprietary health and wellness products.
• MedTech platforms for remote patient monitoring.
• Specialized services like eldercare and rehab.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Relationships

You're looking at how Novo Integrated Sciences, Inc. (NVOS) connects with the people who use their services as of late 2025. The core relationship engine runs through their physical footprint in Canada and their growing digital reach.

Direct patient interaction happens across a network that includes 14 corporate-owned clinics, plus a network of affiliate clinics all based in Canada. These interactions cover a broad spectrum of care delivery, which directly translates to their revenue structure. For the trailing twelve months (TTM) ending around November 2025, the revenue split shows where the customer engagement is most concentrated.

Revenue Segment	TTM Revenue (Approx. Nov 2025)	Percentage of Total TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

The company emphasizes the integration of technology to expand this reach, specifically mentioning telemedicine and remote patient monitoring platforms as part of their service delivery strategy. Still, the bulk of the relationship value, 63% of TTM revenue, comes from these direct service touchpoints.

Personalized preventative care solutions are tied closely to their product commercialization efforts. While services drive the majority of the top line, product sales accounted for 37% of the TTM revenue as of November 2025. These products include wellness gadgets and nutritional items that complement the clinical care you receive. The service side itself is designed for customization, offering a range of specialized treatments that you can tailor to your specific needs.

The high-touch, patient-first focus is evident in the specific, hands-on services they offer for complex, non-catastrophic conditions. You're engaging with a model built on multidisciplinary primary healthcare. The services that define this high-touch relationship include:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions assessment
• Kinesiology

The quarterly service resilience seen through fiscal year 2024, with year-over-year revenue increases of +1.2% in Q1, +3.4% in Q2, and +8.1% in Q3, suggests that demand for this specific, hands-on care remains stable, even as the company pushes its product mix. Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Channels

Novo Integrated Sciences, Inc. (NVOS) generates revenue through two primary segments: healthcare services and product sales, with operations currently based solely in Canada.

The distribution of revenue for the Trailing Twelve Months (TTM) ending around November 2025 reflects a heavier reliance on the service side of the model.

Channel Segment	TTM Revenue (as of Nov 2025)	Percentage of TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

Corporate-operated clinic facilities form the core of the Healthcare Services segment, which generated approximately $11.9 million of the total $13.29 million revenue for the fiscal year ending August 31, 2024.

Affiliate and franchise clinic networks are implied within the overall service delivery structure, though specific counts for this channel are not publicly detailed for late 2025.

Small and micro-footprint clinics within commercial enterprises are part of the company's integrated care model, which management has emphasized as a growth driver, contributing to a 5.75% year-over-year revenue bump in 2024.

Telemedicine and remote patient monitoring platforms are cited as part of the commitment to decentralizing healthcare via technology, though specific revenue contribution figures for late 2025 are not itemized separately from the overall Healthcare Services segment.

Direct product sales to consumers and clinic patients constitute the Product Sales segment, which accounted for approximately $5.00 Million USD of the TTM revenue as of November 2025.

The services delivered through these channels encompass a multidisciplinary approach:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions
• Kinesiology

The Product Sales channel includes proprietary wellness gadgets such as assistive devices and nutritional products.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who pays you is the first step to survival. For Novo Integrated Sciences, Inc. (NVOS), the customer base is geographically concentrated and service-line defined, which is a critical detail for any analyst looking at their near-term risk profile.

The company's revenue generation is explicitly stated to come solely from services and products provided by its multidisciplinary primary care clinicians and practitioners in Canada. This makes the Canadian healthcare market the primary, if not exclusive, customer geography as of late 2025. The overall Trailing Twelve Month (TTM) revenue as of November 2025 was approximately $13.51 Million USD.

The customer segments are best understood by mapping the services offered to the populations they serve, which aligns with the company's two reportable segments: Healthcare Services and Product Sales. Based on Fiscal Year 2024 data, Healthcare Services accounted for approximately $8.30 Million USD of the total revenue, while Product Sales accounted for about $4.92 Million USD.

Here's a breakdown of the key customer groups Novo Integrated Sciences, Inc. (NVOS) targets with its multidisciplinary approach:

• Patients in Canada needing non-catastrophic rehabilitative care.
• Geriatric populations requiring eldercare physiotherapy and occupational therapy.
• Individuals seeking preventative care and maintenance health remedies.
• Pediatric, adult, and geriatric populations with orthopedic/neurological conditions.

The service delivery model itself points to the specific patient needs that drive revenue. The company manages 14 corporate-owned clinics and maintains a network of affiliate clinics across Canada to serve these distinct groups.

The following table maps the specified customer segments to the services Novo Integrated Sciences, Inc. (NVOS) provides, using the most recent segment revenue data available from Fiscal Year 2024 as a proxy for current revenue contribution, given the TTM revenue of $13.51 Million USD.

Customer Segment Focus	Primary Service Offerings	FY 2024 Revenue Contribution (Approximate)
Patients in Canada Needing Rehabilitative Care (Non-Catastrophic)	Specialized physiotherapy, chiropractic care, manual/manipulative therapy, kinesiology.	Majority of the $8.30 Million USD Healthcare Services revenue.
Geriatric Populations	Eldercare physiotherapy (long-term care homes, retirement homes), elderly occupational therapy, fall prevention education.	Significant portion of the $8.30 Million USD Healthcare Services revenue.
Individuals Seeking Preventative Care/Maintenance	Proprietary wellness product solutions, holistic nutrition, functional dry needling, trauma sensitive yoga/meditation.	Contributes to the $4.92 Million USD Product Sales segment and related service revenue.
Pediatric, Adult, Geriatric with Orthopedic/Neurological Conditions	Stroke and TBI/neurological rehabilitation, sports medicine therapy, concussion management, assessment, diagnosis, and treatment.	Substantial component of the $8.30 Million USD Healthcare Services revenue.

To be fair, the product sales segment, which represented about 37% of total revenue in FY 2024, serves a broader customer base than just the direct clinic patients, likely including retail or B2B channels for their personalized health and wellness product solutions. Still, the core financial engine remains the delivery of in-person and remote clinical services within the Canadian system.

The specific services tied to these segments include:

• Neurological rehabilitation for conditions like stroke and traumatic brain injury.
• Women's pelvic health program services.
• Assistive devices provision.
• Dietitian and functional dry needling services.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Novo Integrated Sciences, Inc. (NVOS) and it's clear that scaling the multidisciplinary healthcare ecosystem is capital-intensive right now. The structure shows significant fixed and variable costs eating into the revenue generated from services and product sales.

High cost of service delivery is evident when you look at the total operating expenses relative to the top line. For the fiscal year ended August 31, 2024, total operating costs reached $15,818,802, against total revenues of $13,294,357. The Cost of Revenues alone was $7,551,853 for FY 2024. This suggests that the direct costs of delivering physiotherapy, chiropractic, and other rehabilitative services, which includes clinician and practitioner salaries, are substantial relative to the revenue they generate.

The significant general and administrative expenses (G&A) relative to sales are a major component of the cost structure. For the year ended August 31, 2024, G&A expenses were reported as $14,039,265. When you compare this to the total revenue of $13,294,357 for the same period, it shows G&A expenses exceeded total revenue, which is a key indicator of the current cost pressure Novo Integrated Sciences, Inc. is under.

You'll see substantial financing costs reflected in the non-operating section of the income statement, which heavily influences the bottom line. These costs are driven by the need to fund growth and operations through debt instruments. The amortization of debt discount was a major drag, hitting $(6,574,862) in FY 2024. Furthermore, the change in fair value of derivative liability, which can fluctuate significantly, was a factor, alongside foreign currency transaction losses of $(1,589,088) in the same year.

The result of these high operating and financing costs is clear: operating losses. The Loss from Operations for the year ended August 31, 2024, was $(10,076,298). Ultimately, the FY 2024 net loss was approximately $(16.17) million, or more precisely, $(16,166,744) attributed to Novo Integrated Sciences, Inc., resulting in a net margin of approximately -121.3%.

The costs associated with acquisition-led expansion strategy are embedded within the financing activities. Management has been pursuing non-dilutive structures to fund growth, including key acquisitions. For example, the execution of the $6.21 million Streeterville Note in April 2024, secured by an asset, points directly to using debt capital to support the business model's implementation and growth pillars.

Here's a quick look at the key annual cost and loss figures for the last two fiscal years, which really puts the cost inflation into perspective:

Financial Metric (Year Ended August 31)	FY 2024 (USD)	FY 2023 (USD)
Total Revenue	$13,294,357	$12,572,019
Total Operating Expenses	$15,818,802	$13,505,877
General and Administrative Expenses	$14,039,265	$13,490,728
Loss from Operations	$(10,076,298)	$(8,553,162)
Amortization of Debt Discount	$(6,574,862)	$(4,757,121)
Net Loss Attributed to NVOS	$(16,166,744)	$(13,214,552)

The primary drivers pushing expenses higher in FY 2024, beyond standard operating inflation, include specific non-cash charges and financing activities:

• Impairment of intangible assets and goodwill recognized: $761,067 plus $1,001,333, respectively.
• Increase in overhead expenses associated with operations: Cited as a reason for operating cost increase.
• Amortization of debt discount: Increased by approximately $1.82 million year-over-year.
• Foreign currency transaction losses: Totaled $(1,589,088) in FY 2024.

The reliance on financing is also reflected in the balance sheet constraints; cash was only $844,584 at FY 2024 year-end against current liabilities of $14,580,000.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Revenue Streams

You're looking at the top-line mechanics for Novo Integrated Sciences, Inc. (NVOS) as of late 2025, and the revenue picture is quite concentrated. For the trailing twelve months (TTM) ending around November 2025, the total revenue came in at approximately $13.51 Million USD. This figure is the sum of two distinct, yet integrated, streams. Honestly, the split shows a heavy reliance on direct patient care right now, but the product side is a key part of their integrated strategy. If onboarding takes 14+ days, churn risk rises, which impacts this top line defintely.

Here is the quick math on how that $13.51 Million USD TTM revenue breaks down by segment as of November 2025:

Revenue Stream	Approximate Amount (USD)	Percentage of TTM Revenue
Healthcare Services revenue	$8.51 Million	63%
Product Sales revenue	$5.00 Million	37%
Total Trailing Twelve Months (TTM) Revenue	$13.51 Million	100%

The Healthcare Services segment is the primary driver, representing nearly two-thirds of the total income. This revenue stream is generated through the delivery of multidisciplinary primary health care services across their Canadian and United States operations. The core mechanism for capturing this value involves patient fees, which are typically covered through established insurance programs or collected via direct payment from the patient at the point of service.

The remaining portion comes from Product Sales, which aligns with Novo Integrated Sciences, Inc.'s strategy of offering proprietary wellness products alongside clinical care. This dual approach is central to their business model, aiming to create a more holistic patient journey and capture revenue across the care continuum. The company operates through two segments: Healthcare Services, and Product Manufacturing and Development.

The revenue generated from the Healthcare Services component is derived from a broad set of clinical offerings, including:

• Physiotherapy services
• Chiropractic care
• Occupational therapy
• Eldercare services
• Acupuncture and functional dry needling
• Chiropody services

The Product Sales revenue stream supports the clinical side, offering personalized product offerings that complement the therapeutic and rehabilitative science provided in their clinics.

Finance: draft 13-week cash view by Friday.